

ISOLATION OF A NON-NEUROTOXIC, NON-ENZYMATIC PHOSPHOLIPASE A HOMOLOGUE FROM THE VENOM OF THE AUSTRALIAN TIGER SNAKE *NOTECHIS SCUTATUS SCUTATUS*

James HALPERT and David EAKER

Institute of Biochemistry, University of Uppsala, Box 576, S-751 23 Uppsala, Sweden

Received 23 September 1976

1. Introduction

Snake venom neurotoxins act on the peripheral nervous system, blocking transmission across the cholinergic neuromuscular junction by either a pre- or postsynaptic mode of action. Presynaptic neurotoxins interfere with the release of acetylcholine from the motor nerve terminals and might be useful tools for the investigation of the mechanism of transmitter release.

The most thoroughly characterized presynaptic venom neurotoxins either consist of, or contain as an indispensable part, a structural element which is both structurally and functionally very similar to non- or weakly neurotoxic phospholipases A of various origin. Furthermore, there is a fair amount of indirect evidence that the enzymatic activity might be involved somehow in the toxic action [1–4]. One should like to know which structural features render certain phospholipases A so highly neurotoxic.

The venom of the Australian tiger snake *Notechis scutatus scutatus* contains two highly potent basic phospholipases A, notexin [1, 5–8] and *notechis* II-5* [9], both of which exhibit presynaptic neurotoxic and myotoxic action. Treatment of notexin with *p*-bromophenacyl bromide leads to specific modification of His-48, abolishing by >99% both the phospholipase A and neurotoxic activity, and severely impairing the toxin's ability to bind calcium ions. Notexin and *notechis* II-5 differ in sequence in only seven of 119 positions and show nearly complete

identity in the stretch between Lys-57 and Cys-90, which is the region in which they differ most drastically from a few homologous non- or weakly toxic phospholipases A [10]. If the enzymatic activity of notexin and *notechis* II-5 were merely an evolutionary relic and thus irrelevant to the neuro- and myotoxic actions, one might expect to find in the same venom a toxic protein devoid of catalytic activity [10,11]. Furthermore, comparison of the structure and function of homologous proteins from the same venom offers a means of localizing those structural features responsible for the various activities without the complications introduced by species variation.

Gel filtration of crude tiger snake venom on Sephadex G-75 followed by gradient ion-exchange chromatography on Bio-Rex 70 and elution chromatography on SP-Sephadex yielded a notexin homologue, *notechis* II-1, which is apparently devoid of catalytic, myo- and neurotoxic activities. *Notechis* II-1 binds calcium ions and can be modified with *p*-bromophenacyl bromide as effectively as notexin. Preliminary structural data indicate a high degree of homology with notexin, except for the stretch between Lys-57 and Cys-92.

2. Materials and methods

Gel filtration of the crude venom, ion-exchange chromatography on Bio-Rex 70, reduction and *S*-carboxymethylation, digestion with trypsin, purification of peptides, manual Edman degradation, identification of phenylthiohydantoin derivatives, and amino

* Previously designated toxin 5 or *notechis* 5.

Table 1
Amino acid composition and properties of tiger-snake phospholipase A homologues

Amino acid	<i>notechis</i> II-1	RCM-PBP- <i>notechis</i> II-1 ^a	notexin	TRYP (47–54)
Cm-cysteine		14.33 (14)	14	0.89 (1)
Aspartic acid	14.96 (15)	15.73 (15)	18	2.07 (2)
Threonine	8.89 (9)	8.97 (9)	3	1.00 (1)
Serine	8.97 (9)	8.92 (9)	3	
Glutamic acid	8.28 (8)	8.32 (8)	7	
Proline	5.62 (6)	5.71 (6)	5	
Glycine	6.08 (6)	6.10 (6)	10	
Alanine	10.89 (11)	11.02 (11)	9	1.00 (1)
Half-cystine	14.33 (14) ^b			
Valine	3.09 (3)	2.84 (3)	4	
Methionine	1.22 (1)	0.86 (1)	2	
Isoleucine	3.12 (3)	3.05 (3)	4	
Leucine	4.17 (4)	4.05 (4)	4	
Tyrosine	9.20 (9)	8.92 (9)	10	1.01 (1)
Phenylalanine	2.97 (3)	2.59 (3)	5	
Histidine	1.98 (2)	1.12 (1)	3	(1)
Lysine	8.90 (9)	9.09 (9)	11	
Tryptophan ^c	(2)	(2)	2	
Arginine	4.90 (5)	5.03 (5)	5	1.01 (1)
Total	119	119	119	(8)
Formula weight	13 319		13 578	
Yield (%)	5		5	40
Molar extinction coefficient	25 300 (278 nm)	37 200 (272 nm)	27 000 (278 nm)	23 400 (262 nm)
Number <i>p</i> -bromophenacyl residues per mole		0.84 (1)		1.25 (1)
Specific phospholipase A activity (μ eqv.OH/min/mg protein)	0.4		840	
LD ₁₀₀ (mg/kg mouse)	>20		0.025	
Molar difference extinction coefficient upon calcium binding ^d	1400 (242 nm)		1200 (242 nm)	
Number of calcium binding sites ^d	0.9		1.1	
Protein–calcium dissociation constant (M) ^d	6×10^{-4}		1.4×10^{-4}	

^aPBP = *p*-bromophenacyl.

^bDetermined as cysteic acid.

^cDetermined spectrophotometrically.

^dpH 7.4.

monitoring all separation runs at 262 nm (λ_{\max} for the reagent) in addition to 276 nm and also at 570 nm after alkaline hydrolysis and ninhydrin reaction. The amino acid composition of the modified peptide TRYP (47–54) is given in table 1. Seven cycles of Edman degradation established the sequence

PBB 50
Thr–His–Asp–Asp–Cys–Tyr–Ala–Arg

which differs from the corresponding stretch in notexin at three positions.

The partial sequence of *notechis* II-1 is shown in figure 2. There appears to be a high degree of homology between *notechis* II-1 and notexin in the first half of the sequences. Of the 13 substitutions indicated in the first 57 positions, only Ser/Gly at position 26 involves a hitherto invariant residue in phospholipases

Table 2
Relative activities of snake venom phospholipase A homologues

	Lethality	Myotoxicity ^a	Phospholipase A
Notexin	100	100	100
<i>Notechis II-5</i>	42	20	165
<i>Naja nigricollis</i>	2.5	2	31
PBP-Notexin	0.25	1	0.21
<i>Notechis II-1</i>	< 0.10	0	0.05

^aThe myotoxicity assays were kindly performed by Dr John B. Harris.

^bPBP = *p*-bromophenacyl.

In a previous communication [1] the myotoxicity of this notexin derivative was erroneously reported to be only somewhat less than that of the native.

A [10]. Furthermore, there is a high degree of identity in those two stretches, the integrity of which has been shown to be essential to enzymatic activity in porcine pancreatic phospholipase A; namely, the amino terminus, which is involved in interaction with micellar interfaces [13], and the stretch around His-48, which is involved in binding metal ions and monomeric substrates [14].

There is also a high degree of identity in the last fourth of the sequences, and none of the seven assumed substitutions in the last 28 positions involves hitherto invariant residues. The homology seems to break down, however, in the stretch between Lys-57 and Cys-92 (not shown), and it is impossible even to align, let alone infer the sequences of the tryptic peptides from this stretch in *notechis II-1*. It is tempting to conclude that some structural deficiency in the region 58–91 in the *notechis II-1* sequence is responsible for the lack of both catalytic and toxic activity.

Acknowledgements

We thank Ragnar Thorzelius and Sven Centring for expert assistance with the amino acid analysis and Jan Fohlman for help with the Edman degradation. This investigation was supported by the Swedish Natural Science Research Council (dnr 2859-008).

References

- [1] Halpert, J., Eaker, D. and Karlsson, E. (1976) FEBS Lett. 61, 72–76.
- [2] Wernicke, J. F., Vanker, A. D. and Howard, B. D. (1975) J. Neurochem. 25, 483–496.
- [3] Strong, P. N., Goerke, J., Oberg, S. G. and Kelly, R. B. (1976) Proc. Natl. Acad. Sci. USA 73, 178–182.
- [4] Howard, B. D. (1975) Biochem. Biophys. Res. Commun. 67, 58–65.
- [5] Karlsson, E., Eaker, D. and Rydén, L. (1972) Toxicon 10, 405–413.




Fig.2. Partial amino acid sequence of *notechis II-1*. Assignments set off by commas are inferred on the basis of the composition of tryptic peptides and homology with notexin. Residues 1–17 and 47–54 were determined by manual Edman degradation.

- [6] Harris, J. B., Karlsson, E. and Thesleff, S. (1973) *Br. J. Pharmacol.* 47, 141–146.
- [7] Harris, J. B., Johnson, M. A. and Karlsson, E. (1975) *Clin. Exp. Pharmacol. Physiol.* 2, 383–404.
- [8] Halpert, J. and Eaker, D. (1975) *J. Biol. Chem.* 250, 6990–6997.
- [9] Halpert, J. and Eaker, D. (1976) *J. Biol. Chem.*, in press.
- [10] Eaker, D. (1975) in: *Peptides: Chemistry, Structure, and Biology* (Walter, R. and Meienhofer, J., eds), pp. 17–30, Ann Arbor Science Publishers, Ann Arbor.
- [11] Eaker, D., Halpert, J., Fohlman, J. and Karlsson, E. (1976) in: *Animal, Plant, and Microbial Toxins* (Ohsaka, A., ed) Vol. 2, pp. 27–45, Plenum, New York.
- [12] Fohlman, J., Eaker, D., Karlsson, E. and Thesleff, S. (1976) *Eur. J. Biochem.*, in press.
- [13] Dam-Mieras, M. C. E. van, Slotboom, A. J., Pieterse, W. A. and Haas, G. H. de (1975) *Biochemistry* 14, 5387–5394.
- [14] Volwerk, J. J., Pieterse, W. A. and Haas, G. H. de (1974) *Biochemistry* 13, 1446–1454.